CGTX - Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS Indications | Benzinga
Complete EEG results from SEQUEL study to be unveiled, demonstrating beneficial impact of CT1812 on brain synaptic function
CT1812 START study in early Alzheimer's disease allows approved monoclonal antibody as background therapy – featured as late-breaking, oral presentation
PURCHASE, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (NASDAQ:CGTX), (the "Company" or "Cognition") announced upcoming presentations from studies of CT1812, the Company's lead candidate for the treatment of adults with early, mild and moderate Alzheimer's disease at the Clinical Trials on Alzheimer's Disease (CTAD) conference being held October 24-27, 2023 virtually and in person in Boston, MA.
Cognition scientists and collaborators will present the complete electroencephalography (EEG) findings and proteomic analyses from the SEQUEL study. Prior topline results showed that CT1812 had a beneficial impact on synapse function as measured by a positive change in brain waves patterns observed using quantitative EEG. Specifically, participants treated with CT1812 exhibited fewer slow "theta" waves, which are associated with cognitive impairment, and proportionally more "alpha" waves compared to placebo-treated participants. CT1812 also improved connectivity, as assessed by alpha AECc, which may indicate improved communication between different parts of the brain.
An oral late-breaking presentation will also discuss the Phase 2 study design of the company's ongoing START study, which is enrolling adults with early Alzheimer's disease. Participants in START will be permitted to be on stable background therapy with lecanemab, an FDA-approved anti-amyloid antibody.
"The approval of monoclonal antibody therapies against amyloid beta (A?) protofibrils represents an important milestone in Alzheimer's drug development, but industry experts agree that combination treatments will likely be required to achieve greater impact on the disease," explained Anthony Caggiano, MD, Ph.D., Cognition's CMO and head of R&D. "To this end, we and our colleagues at the National Institute of Aging and the Alzheimer's Clinical Trials Consortium (ACTC) made the strategic decision to allow participants to enroll in the ongoing Phase 2 START study who are being administered lecanemab. We believe this will allow us to assess the benefit of CT1812 in real-world conditions."
Cognition Therapeutics at CTAD:
| Title: |
| A Pilot Electroencephalography (EEG) Study to Evaluate the Effect of CT1812 Treatment on Synaptic Activity in Subjects with Mild to Moderate Alzheimer's Disease (LP024) |
| Authors: |
| De Haan W, Caggiano AO, Scheltens P, Grundman M, Scheijbeler E, Hamby ME, Vijverberg E |
| Title: |
| Proteomic Analysis of Plasma in a Phase 2 Clinical Trial in Alzheimer's Patients to Identify Pharmacodynamic Biomarkers of the S2R Modulator CT1812 (P075) |
| Authors: |
| Lizama B, Cho E, Duong D, Pandey K, Williams C, Caggiano AO, Seyfried N, Di Caro V, Hamby ME |
| Title: |
| Proteomic Analysis in a Phase 2 Clinical Trial Studying CT1812 to Identify CSF and Plasma Pharmacodynamic Biomarkers and Molecular Correlates of EEG in Alzheimer's Patients (LP057) |
| Authors: |
| Di Caro V, Pandey K, Lizama B, ... |